Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by WINTON GROUP Ltd

WINTON GROUP Ltd lowered its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 8.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,884 shares of the pharmaceutical company’s stock after selling 624 shares during the period. WINTON GROUP Ltd’s holdings in Vertex Pharmaceuticals were worth $2,772,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Artisan Partners Limited Partnership raised its position in Vertex Pharmaceuticals by 20.8% during the 4th quarter. Artisan Partners Limited Partnership now owns 664,523 shares of the pharmaceutical company’s stock worth $267,603,000 after buying an additional 114,250 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of Vertex Pharmaceuticals by 8.1% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 438,091 shares of the pharmaceutical company’s stock worth $178,351,000 after acquiring an additional 32,739 shares during the period. Ausdal Financial Partners Inc. raised its holdings in Vertex Pharmaceuticals by 6.0% during the fourth quarter. Ausdal Financial Partners Inc. now owns 757 shares of the pharmaceutical company’s stock worth $305,000 after purchasing an additional 43 shares in the last quarter. Murphy & Mullick Capital Management Corp acquired a new stake in Vertex Pharmaceuticals in the fourth quarter valued at about $1,313,000. Finally, Meiji Yasuda Asset Management Co Ltd. boosted its holdings in Vertex Pharmaceuticals by 1.5% in the 4th quarter. Meiji Yasuda Asset Management Co Ltd. now owns 13,263 shares of the pharmaceutical company’s stock valued at $5,341,000 after purchasing an additional 193 shares in the last quarter. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Insider Transactions at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP David Altshuler sold 3,231 shares of the company’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the completion of the sale, the executive vice president now directly owns 26,512 shares in the company, valued at $13,256,000. This represents a 10.86 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Ourania Tatsis sold 530 shares of the business’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $475.34, for a total value of $251,930.20. Following the sale, the executive vice president now owns 58,539 shares of the company’s stock, valued at $27,825,928.26. The trade was a 0.90 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 4,315 shares of company stock worth $2,121,012 in the last ninety days. Insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Stock Up 0.5 %

Shares of NASDAQ:VRTX opened at $502.55 on Friday. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01. The firm has a market cap of $129.05 billion, a price-to-earnings ratio of -228.43, a PEG ratio of 2.11 and a beta of 0.41. The stock’s 50-day moving average price is $475.04 and its two-hundred day moving average price is $463.61. Vertex Pharmaceuticals Incorporated has a 12-month low of $377.85 and a 12-month high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. On average, research analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Analyst Ratings Changes

VRTX has been the subject of several recent analyst reports. Morgan Stanley raised their price target on Vertex Pharmaceuticals from $450.00 to $459.00 and gave the company an “equal weight” rating in a report on Tuesday, February 11th. Royal Bank of Canada boosted their target price on shares of Vertex Pharmaceuticals from $407.00 to $408.00 and gave the stock a “sector perform” rating in a research report on Thursday, February 20th. Truist Financial increased their price target on shares of Vertex Pharmaceuticals from $460.00 to $520.00 and gave the company a “buy” rating in a report on Tuesday, February 11th. JPMorgan Chase & Co. decreased their price objective on shares of Vertex Pharmaceuticals from $503.00 to $500.00 and set an “overweight” rating on the stock in a report on Monday, December 23rd. Finally, BMO Capital Markets set a $545.00 target price on shares of Vertex Pharmaceuticals in a report on Friday, January 31st. Ten equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $506.70.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.